If you work in a cath lab and you would like to make more money, take some pointers from SpringBoard Healthcare’s 2015 survey. The survey results shed light on wage information from directors and managers to nurses and techs.

Fewer than 10 percent of older adults received an implantable cardioverter-defibrillator (ICD) following an MI, according to an analysis of Medicare beneficiaries who had low ejection fraction. Although the patients were at an increased risk of sudden cardiac death, only 8.1 percent were implanted with the device within a year of their MI event.

The FDA approved Medtronic’s CoreValve Evolut R device on June 23, giving physicians in the U.S. who perform transcatheter aortic valve replacement (TAVR) procedures the ability to recapture and reposition a valve during implantation.

Here’s a bridge you may consider burning: anticoagulation bridging therapy for patients with atrial fibrillation who undergo an elective operation. A randomized clinical trial found no bridging after discontinuing warfarin led to no more thromboembolic events than bridging, with a lower risk of bleeding.

A prospective analysis found 4.3 percent of sudden cardiac deaths in San Francisco were in patients with pacemakers or implantable cardioverter-defibrillators (ICDs). Half of the deaths were related to the devices, and the most common cause of death was ventricular tachycardia or ventricular fibrillation.

The FDA approved cangrelor on June 22 for adults undergoing PCI. The intravenous medication is an antiplatelet drug and is intended to prevent blood clots.

Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally, the Endurant AAA stent graft system from Medtronic plc (NYSE: MDT) maintained durable, consistent and proven outcomes through five years of follow-up in the company’s U.S. clinical study of the implantable medical device, according to new clinical data presented today at the Society for Vascular Surgery’s “Vascular Annual Meeting.”

Medtronic expanded its reach in the endovascular market with the acquisition of Aptus Endosystems, a company that specializes in advanced technology for endovascular aneurysm repair and thoracic endovascular aneurysm repair.